MARKET

ICAD

ICAD

Icad Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.630
+0.010
+0.28%
After Hours: 3.630 0 0.00% 16:17 05/19 EDT
OPEN
3.600
PREV CLOSE
3.620
HIGH
3.760
LOW
3.470
VOLUME
129.19K
TURNOVER
0
52 WEEK HIGH
19.00
52 WEEK LOW
2.910
MARKET CAP
91.41M
P/E (TTM)
-6.9275
1D
5D
1M
3M
1Y
5Y
New Real-World Evidence Shows ProFound AI Improves Cancer Detection and Accuracy with Digital Breast Tomosynthesis, or 3D Mammography
Research presented at the 2022 SBI/ACR Breast Imaging Symposium confirms ProFound AI significantly enhances radiologists’ screening performanceNASHUA, N.H., May 18, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader prov...
GlobeNewswire · 1d ago
36 of the Best Ideas Companies to Present at the Spring into Action - Best Ideas Investor Conference on May 16th - 20th, 2022
RALEIGH, NC / ACCESSWIRE / May 16, 2022 / The Spring into Action- Best Ideas Virtual Investor Conference will take place on May 16th \- 20th, 2022, where 36 SmallCap, MicroCap and NanoCap public companies will be presenting via virtual webcast to a global ...
ACCESSWIRE · 3d ago
New Research Finds iCAD's ProFound AI Risk for Digital Breast Tomosynthesis is 2.4x More Accurate than Traditional Lifetime Risk Models
Using U.S. guidelines, ProFound AI Risk found 14% of women studied who had a negative screen had almost 20 times higher risk of developing breast cancer in the next year than the general risk populationNASHUA, N.H., May 16, 2022 (GLOBE NEWSWIRE) -- iCAD, I...
GlobeNewswire · 3d ago
iCAD to Present at the Spring Into Action - Best Ideas Virtual Investor Conference on May 17th, 2022
NASHUA, NH / ACCESSWIRE / May 12, 2022 /iCAD, Inc. (NASDAQ:ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Company will present at the Spring Into Action - Best Ideas Virtual Invest...
ACCESSWIRE · 05/12 19:30
icad: Q1 Earnings Insights
icad (NASDAQ:ICAD) reported its Q1 earnings results on Wednesday, May 11, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings icad missed estimated earnings by 16.67%, reporting an EPS of $-0.14 versus an estimate of $-0.1...
Benzinga · 05/11 22:35
Icad (ICAD) Reports Q1 Loss, Tops Revenue Estimates
Icad (ICAD) delivered earnings and revenue surprises of -40% and 0.37%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/11 22:05
BRIEF-iCAD Reports Q1 Loss Per Share Of $0.14
reuters.com · 05/11 21:55
iCAD Non-GAAP EPS of -$0.14 misses by $0.01, revenue of $7.52M beats by $0.1M
iCAD press release (NASDAQ:ICAD): Q1 Non-GAAP EPS of -$0.14 misses by $0.01. Revenue of $7.52M (-13.0% Y/Y) beats by $0.1M.
Seekingalpha · 05/11 20:20
More
No Data
Learn about the latest financial forecast of ICAD. Analyze the recent business situations of Icad Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

33.33%Strong Buy
66.67%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ICAD stock price target is 13.83 with a high estimate of 23.00 and a low estimate of 8.00.
High23.00
Average13.83
Low8.00
Current 3.630
EPS
Actual
Estimate
-0.14-0.10-0.07-0.03
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 122
Institutional Holdings: 15.85M
% Owned: 62.95%
Shares Outstanding: 25.18M
TypeInstitutionsShares
Increased
30
1.01M
New
15
714.31K
Decreased
26
926.00K
Sold Out
14
1.33M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
+2.04%
Healthcare Equipment & Supplies
+1.30%
Key Executives
Non-Executive Chairman/Independent Director
Timothy Irish
President/Chief Executive Officer/Director
Stacey Stevens
Chief Financial Officer/Secretary
Charles Carter
Chief Technology Officer
Jonathan Go
Lead Director/Independent Director
Nathaniel Dalton
Director
Michael Klein
Independent Director
Dana Brown
Independent Director
Rakesh Patel
Independent Director
Andrew Sassine
Independent Director
Susan Wood
No Data
No Data
About ICAD
iCAD, Inc. is a global medical technology company providing cancer detection and therapy solutions. The Company operates through two segments: Cancer Detection (Detection) and Cancer Therapy (Therapy). The Detection segment consists of its image analysis and workflow products, a range of Artificial Intelligence (AI), Computer-Aided Detection (CAD) systems and workflow solutions for two-dimensional (2D) and three-dimensional (3D) mammography, Magnetic Resonance Imaging (MRI) and Computed Tomography (CT). The Therapy segment consists of its radiation therapy products and offers the Xoft System, which is an isotope-free cancer treatment platform technology. The Company sells its products through its direct sales organization, as well as through various original equipment manufacturer partners, distributors and resellers.

Webull offers kinds of iCAD Inc stock information, including NASDAQ:ICAD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ICAD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ICAD stock methods without spending real money on the virtual paper trading platform.